APOE ε4 allele is associated with cognitive impairment in patients with multiple sclerosis

Neurology

Volumn 70, Issue 3, 2008, Pages 185-190

  Shi, J ^a   Zhao, C B ^a   Vollmer, T L ^a   Tyry, T M ^a   Kuniyoshi, S M ^b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4;

ADULT; ARTICLE; COGNITION; COGNITIVE DEFECT; FEMALE; GENETIC POLYMORPHISM; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; MEMORY; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; AGED; BRAIN; COHORT ANALYSIS; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; PSYCHOLOGICAL ASPECT; SENSITIVITY AND SPECIFICITY; STANDARD;

ADULT; AGED; APOLIPOPROTEIN E4; BRAIN; COGNITION DISORDERS; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 38149003882     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000264004.62612.44     Document Type: Article

References (36)

1. Beatty WW, Goodkin DE, Monson N, Beatty PA, Hertsgaard D. Anterograde and retrograde amnesia in patients with chronic progressive multiple sclerosis. Arch Neurol 1988;45:611-619.
2. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction Neurology 1991;41:685-691.
3. Benedict RH, Fischer JS, Archibald CJ, et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol 2002;16:381-397.
4. Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 2001;58:1602-1606.
5. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning Neurology 1991;41:692-696.
6. Amato MP, Ponziani G, Pracucci G, Bracco L, Siracusa G, Amaducci L. Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol 1995;52:168-172.
7. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 1994;17:525-530.
8. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994;264:850-852.
9. Holtzman DM, Fagan AM. Potential role of apoE in structural plasticity in the nervous system; implications for disorders of the central nervous system. Trends Cardiovasc Med 1998;8:250-255.
10. Holtzman DM, Pitas RE, Kilbridge J, et al. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc Natl Acad Sci USA 1995;92:9480-9484.
11. Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000;97:2892-2897.
12. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006;314:777-781.
13. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977-1981.
14. Ashford JW. APOE genotype effects on Alzheimer's disease onset and epidemiology. J Mol Neurosci 2004;23:157-165.
15. Evangelou N, Jackson M, Beeson D, Palace J. Association of the APOE epsilon4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999;67:203-205.
16. Fazekas F, Strasser-Fuchs S, Kollegger H, et al. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. Neurology 2001;57:853-857.
17. Schmidt S, Barcellos LF, DeSombre K, et al. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am J Hum Genet 2002;70:708-717.
18. Burwick RM, Ramsay PP, Haines JL, et al. APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers. Neurology 2006;66:1373-1383.
19. Martins CA, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology 2005;65:1888-1893.
20. Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol 2005;62:454-459.
21. Oliveri RL, Cittadella R, Sibilia G, et al. APOE and risk of cognitive impairment in multiple sclerosis. Acta Neurol Scand 1999;100:290-295.
22. Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T. Changes in the ascertainment of multiple sclerosis. Neurology 2005;65:1066-1070.
23. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005;58:840-846.
24. Hamilton M. Rating depressive patients. J Clin Psychiatry 1980;41:21-24.
25. Rao SM. Cognitive Function Study Group, NMSS. A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis. New York: National Multiple Sclerosis Society, 1990.
26. Artiga MJ, Bullido MJ, Frank A, et al. Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene. Hum Mol Genet 1998;7:1887-1892.
27. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
28. Weisgraber KH, Mahley RW. Human apolipoprotein E: the Alzheimer's disease connection. FASEB J 1996;10:1485-1494.
29. Kujala P, Portin R, Ruutiainen J. The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain 1997;120(Pt 2):289-297.
30. Piras MR, Magnano I, Canu ED, et al. Longitudinal study of cognitive dysfunction in multiple sclerosis: neuropsychological, neuroradiological, and neurophysiological findings. J Neurol Neurosurg Psychiatry 2003;74:878-885.
31. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci 2006;31:445-454.
32. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA 2006;103:5644-5651.
33. Pham T, Kodvawala A, Hui DY. The receptor binding domain of apolipoprotein E is responsible for its antioxidant activity. Biochemistry 2005;44:7577-7582.
34. Stoll G, Meuller HW, Trapp BD, Griffin JW. Oligodendrocytes but not astrocytes express apolipoprotein E after injury of rat optic nerve. Glia 1989;2:170-176.
35. Klages JD, Fisk JD, Rockwood K. APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 2003;15:1-5.
36. Pinholt M, Frederiksen JL, Christiansen M. The association between apolipoprotein E and multiple sclerosis. Eur J Neurol 2006;13:573-580.